Kalvista Pharmaceuticals, INC 8-K filings

Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals for $27.00 per share in an all-cash transaction.

Chiesi Group announced its definitive agreement to acquire KalVista Pharmaceuticals for approximately $1.9 billion in cash, significantly expanding its rare disease portfolio with KalVista's oral HAE therapy.

KalVista Pharmaceuticals reported $49.1 million in EKTERLY net product revenue for the eight-month transition period ended December 31, 2025, driven by rapid US adoption and international expansion.

KalVista Pharmaceuticals announced preliminary Q4 and full-year 2025 revenue for EKTERLY, exceeding expectations with strong patient adoption and international expansion.

KalVista Pharmaceuticals reports strong initial US sales for EKTERLY, expands globally, and secures funding to reach profitability.

KalVista Pharmaceuticals appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer to bolster global EKTERLY launch.

KalVista Pharmaceuticals announced the appointment of Bethany Sensenig to its Board of Directors and Audit Committee, alongside the successful adoption of all proposals at its 2025 Annual Meeting of Stockholders.

KalVista Pharmaceuticals successfully completed an upsized private placement of $143.75 million in 3.250% Convertible Senior Notes due 2031, bolstering its financial position for EKTERLY commercialization and general corporate purposes.

KalVista Pharmaceuticals announced FDA and UK approval for EKTERLY, its oral HAE treatment, initiated US launch with strong early demand, and reported fiscal Q1 2025 financial results.

KalVista Pharmaceuticals announced the date for its 2026 Annual Meeting of Stockholders and updated deadlines for stockholder proposals and director nominations.

KalVista Pharmaceuticals announced the landmark FDA approval of EKTERLY (sebetralstat) as the first and only oral on-demand treatment for hereditary angioedema, alongside fiscal year 2025 financial results showing a strengthened cash position and new international commercialization agreements.

KalVista Pharmaceuticals, Inc. announced the U.S. FDA approval of EKTERLY (sebetralstat), the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Jebediah T. Ledell resigned from his position as Chief Operating Officer of KalVista Pharmaceuticals, effective May 12, 2025.

KalVista Pharmaceuticals grants Kaken Pharmaceutical commercialization rights in Japan for sebetralstat, an investigational oral treatment for hereditary angioedema (HAE), securing an upfront payment and potential milestones.

KalVista Pharmaceuticals' Board of Directors has approved a change in the company's fiscal year-end from April 30 to December 31, effective for the fiscal year beginning January 1, 2026.

KalVista Pharmaceuticals announces positive third fiscal quarter results, highlighted by progress with sebetralstat and key regulatory milestones.

KalVista Pharmaceuticals has appointed Jeb Ledell as its new Chief Operating Officer, effective December 16, 2024.

KalVista Pharmaceuticals announced its second fiscal quarter results, highlighted by the FDA's acceptance of the New Drug Application for sebetralstat and a significant capital raise to support its commercial launch.

KalVista Pharmaceuticals has appointed Laurence Reid, Ph.D., to its Board of Directors, effective immediately, bringing extensive biopharmaceutical experience to the company.

KalVista Pharmaceuticals has announced a $55 million public offering of common stock and a concurrent $5 million private placement to fund clinical development and commercialization efforts.

KalVista Pharmaceuticals has entered into a royalty financing agreement with DRI Healthcare Trust, securing up to $179 million to support the commercial launch of their drug sebetralstat.

KalVista Pharmaceuticals held its 2024 Annual Meeting of Stockholders, where key proposals including the election of directors and ratification of the accounting firm were approved.

KalVista Pharmaceuticals has appointed Brian Piekos as its new Chief Financial Officer, effective September 9, 2024.

KalVista Pharmaceuticals announced its first fiscal quarter results, highlighted by the FDA accepting the NDA for sebetralstat and the EMA validating the MAA submission.

KalVista Pharmaceuticals has entered into a lease agreement for a new corporate headquarters and laboratory space in Framingham, MA, with an expected commencement date of April 30, 2025.

KalVista Pharmaceuticals submitted a New Drug Application (NDA) for sebetralstat, a potential oral treatment for hereditary angioedema (HAE), and reported its fiscal year 2024 financial results.

KalVista Pharmaceuticals has appointed William C. Fairey to its Board of Directors, effective immediately, bringing significant commercial and medical expertise.

KalVista Pharmaceuticals reports successful Phase 3 trial results for sebetralstat and a CEO transition as it moves towards commercialization.

KalVista Pharmaceuticals has appointed Benjamin L. Palleiko as its new CEO, effective immediately, following the resignation of Andrew Crockett, marking a planned transition as the company moves towards commercialization.

KalVista Pharmaceuticals has announced a public offering to raise $160.1 million through the sale of common stock and pre-funded warrants.